Option chain shows key data for American Cryostem Corp's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for American Cryostem Corp.

American Cryostem Corp (OTC:CRYO) Stock, Option Chain

News

Guidance

Contracts

Management

Global

CRYO

LIFS

Life Stem Genetics, American CryoStem Announce Collaboration

Legal

American CryoStem Awarded Patent for Cell Culture Media  

American Cryostem Corp

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International Inc

CryoPort Inc

CRYOMASS TECHNOLOGIES INC by Cryomass Technologies Inc.

Cryomass Technologies Inc

FDA Recently Inspected American Cryostem And Found It Was Processing Adipose Tissue Into ATCELL And Marketing It Without Approval

Earnings

CyroLife Reports Q1 EPS $0.10 Vs Est $0.00, Sales $43M Vs Est $41M

Life Stem Genetics (OTC: <a class="ticker" href="/stock/lifs#OTC">LIFS</a>) announced today a strategic 
 collaborative agreement with American CryoStem Corporation, 
 (OTC: <a class="ticker" href="/stock/cryo#OTC">CRYO</a>). CRYO is a leading developer, marketer and global licensor 
 of patented adipose tissue-based cellular technologies for the 
 Regenerative and Personalized Medicine industries.
 Adipose tissue is an anatomical term for loose connective tissue (fat) 
 composed of adipocytes (cells). It is used in LIFS stem cell procedures 
 and currently is extracted via liposuction each time a patient has a 
 treatment. This collaboration will give our physician's network the 
 ability to store a patient's adipose tissue for future regenerative 
 medicine applications after only one extraction process. In the absence 
 of future liposuction procedures, the patient's recovery time is 
 <a href="http://www.benzinga.com/pressreleases/13/11/b4102538/life-stem-genetics-announces-collaborative-agreement-with-american-cryo">See full press release</a>

American CryoStem Corporation (OTCBB: CRYO) announced the grant to it of a patent by the United States Patent Office (USPTO). 

American CryoStem Corporation (the "Company") has been awarded U.S. Patent Number 7,989,205, entitled "Cell Culture Media, Kits, and Methods of Use" (the "Patent"), by the USPTO. This Patent covers a unique product for cellular growth in the processing of adult stem cells. This is significant to the Company for the advancement of its research, clinical and cosmetic applications. The Company's management believes that the Patent will support the Company's efforts in its goal to establish itself as a leader in the preparation of autologous stem cells for use in regenerative medicine. The Patent includes a specific human formulation to overcome the concerns and issues prevalent in the FDA's and other regulatory agencies' guidance when using non-human biologic materials in the preparation of stem cells for human use.

Comments

American Cryostem Corp

American Cryostem Corp (CRYO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga